Beta Thalassemia

Mendelian MONDO:0019402 Pathograph 14 Hematological Disease Genetic Disease

Ask OpenScientist

Ask a research question about Beta Thalassemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
18
Phenotypes
14
Pathograph
4
Genes
8
Treatments
3
Subtypes
12
References
2
Deep Research
👪

Inheritance

1
Autosomal recessive
◆

Subtypes

3
Beta Thalassemia Minor (Trait)
Heterozygous carriers with one normal and one affected HBB allele. Usually asymptomatic or mild microcytic anemia. Identified by elevated HbA2.
Beta Thalassemia Intermedia
Moderate disease severity, typically homozygous or compound heterozygous for mild HBB mutations. Patients may require intermittent transfusions.
Beta Thalassemia Major (Cooley Anemia)
Severe transfusion-dependent anemia due to homozygous or compound heterozygous severe HBB mutations. Presents in first 1-2 years of life.
⚙

Pathophysiology

6
Defective Beta-Globin Synthesis
Mutations in the HBB gene reduce or abolish beta-globin chain production. Beta-zero (beta0) mutations produce no beta-globin; beta-plus (beta+) mutations produce reduced amounts. Over 300 mutations have been identified, including point mutations, small deletions, and rarely large deletions.
erythroblast link
HBB link
hemoglobin biosynthetic process link ↓ DECREASED
Downstream
Alpha-Globin Chain Excess Reduced beta-globin leads to unpaired alpha-globin chains that precipitate and damage erythroid precursors.
Show evidence (1 reference)
PMID:20492708 SUPPORT Human Clinical
"Beta-thalassemias are caused by point mutations or, more rarely, deletions in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent (beta0) synthesis of the beta chains of hemoglobin (Hb)."
Confirms that HBB mutations lead to reduced or absent beta-globin chain synthesis.
Alpha-Globin Chain Excess
Excess unpaired alpha-globin chains precipitate as insoluble aggregates in erythroid precursors, causing oxidative membrane damage, apoptosis of erythroblasts (ineffective erythropoiesis), and shortened survival of mature red blood cells (hemolysis). This is the central pathogenic mechanism distinguishing beta-thalassemia from alpha-thalassemia.
erythroblast link
HBA1 link HBA2 link
response to oxidative stress link ↑ INCREASED apoptotic process link ↑ INCREASED
Downstream
Ineffective Erythropoiesis Apoptosis of alpha-chain-laden erythroid precursors in the bone marrow.
Chronic Hemolysis Surviving erythrocytes with membrane damage are cleared prematurely.
Show evidence (1 reference)
PMID:21705976 SUPPORT Human Clinical
"unbalanced alpha globin chain synthesis results in severely rheologically compromised erythrocytes with premature destruction in the peripheral circulation and ineffective erythropoiesis within the bone marrow and in extramedullary sites"
Confirms that excess alpha-globin chains cause both peripheral erythrocyte destruction and ineffective erythropoiesis.
Ineffective Erythropoiesis
Massive expansion of erythroid precursors in bone marrow and extramedullary sites, but most cells undergo apoptosis before maturing. This drives erythroid hyperplasia, skeletal deformities (marrow expansion), and inappropriately low reticulocyte output relative to the degree of erythroid expansion.
erythroid progenitor cell link
erythrocyte differentiation link ⚠ ABNORMAL erythrocyte homeostasis link ⚠ ABNORMAL
Downstream
Iron Overload Ineffective erythropoiesis suppresses hepcidin, increasing intestinal iron absorption and leading to iron overload even without transfusions.
Show evidence (1 reference)
PMID:22631035 SUPPORT Human Clinical
"Ineffective erythropoiesis is the hallmark of beta-thalassemia that triggers a cascade of compensatory mechanisms resulting in clinical sequelae such as erythroid marrow expansion, extramedullary hematopoiesis, splenomegaly, and increased gastrointestinal iron absorption."
Confirms ineffective erythropoiesis as the hallmark mechanism driving marrow expansion, extramedullary hematopoiesis, and iron absorption.
Chronic Hemolysis
Peripheral destruction of abnormal erythrocytes with membrane damage from precipitated alpha-globin chains. Leads to anemia, jaundice, splenomegaly, and gallstones.
erythrocyte link macrophage link
erythrocyte homeostasis link ⚠ ABNORMAL positive regulation of erythrocyte clearance link ↑ INCREASED
Downstream
Iron Overload Iron released from hemolyzed red cells contributes to iron loading.
Show evidence (1 reference)
PMID:21705976 SUPPORT Human Clinical
"unbalanced alpha globin chain synthesis results in severely rheologically compromised erythrocytes with premature destruction in the peripheral circulation"
Confirms peripheral destruction of rheologically compromised erythrocytes (hemolysis).
Iron Overload
Iron accumulation from transfusional hemosiderosis and increased intestinal absorption (due to hepcidin suppression from ineffective erythropoiesis). Iron deposits in heart, liver, and endocrine organs cause cardiomyopathy, liver fibrosis, diabetes, and hypogonadism.
hepatocyte link
HAMP link
intracellular iron ion homeostasis link ⚠ ABNORMAL iron ion transport link ↑ INCREASED
Show evidence (2 references)
PMID:21705976 SUPPORT Human Clinical
"erythropoiesis,anemia and hypoxia down-regulate hepcidin, the master regulator of iron homeostasis. Hepcidin deficiency in turn allows excessive duodenal iron absorption and development of systemic iron overload."
Confirms hepcidin suppression from ineffective erythropoiesis as the mechanism of iron overload.
PMID:20492708 SUPPORT Human Clinical
"Regular transfusion therapy leads to iron overload-related complications including endocrine complication (growth retardation, failure of sexual maturation, diabetes mellitus, and insufficiency of the parathyroid, thyroid, pituitary, and less commonly, adrenal glands), dilated myocardiopathy,..."
Confirms iron overload complications affecting heart, liver, and endocrine organs.
Fetal Hemoglobin Modulation
Genetic modifiers that increase fetal hemoglobin (HbF) production ameliorate disease severity by compensating for deficient adult hemoglobin (HbA) and reducing free alpha-globin chains. Key modifiers include BCL11A, HBS1L-MYB locus, and KLF1.
erythroid progenitor cell link
BCL11A link KLF1 link MYB link HBS1L link
regulation of hemoglobin biosynthetic process link
Show evidence (1 reference)
PMID:18691915 PARTIAL Human Clinical
"In this study, we showed that SNPs in BCL11A were associated with F-cell numbers in Chinese with beta-thalassemia trait, and with HbF levels in Thais with either beta-thalassemia or HbE trait and in African Americans with sickle cell anemia."
Provides beta-thalassemia-specific evidence that BCL11A variants modulate HbF-related traits.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Beta Thalassemia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

18
Blood 7
Microcytic Hypochromic Anemia VERY_FREQUENT Hypochromic microcytic anemia (HP:0004840)
Show evidence (1 reference)
PMID:20492708 SUPPORT Human Clinical
"Individuals with thalassemia major usually present within the first two years of life with severe anemia, requiring regular red blood cell (RBC) transfusions."
Confirms severe anemia as the defining presentation of thalassemia major.
Decreased Mean Corpuscular Volume VERY_FREQUENT Decreased mean corpuscular volume (HP:0025066)
Reticulocytosis FREQUENT Reticulocytosis (HP:0001923)
Erythroid Hyperplasia VERY_FREQUENT Erythroid hyperplasia (HP:0012132)
Persistence of Hemoglobin F VERY_FREQUENT Persistence of hemoglobin F (HP:0011904)
Target Cells VERY_FREQUENT Target cells (HP:0034280)
Extramedullary Hematopoiesis FREQUENT Extramedullary hematopoiesis (HP:0001978)
Cardiovascular 3
Splenomegaly VERY_FREQUENT Splenomegaly (HP:0001744)
Cardiomyopathy FREQUENT Cardiomyopathy (HP:0001638)
Pulmonary Hypertension OCCASIONAL Elevated pulmonary artery pressure (HP:0004890)
Digestive 3
Hepatomegaly FREQUENT Hepatomegaly (HP:0002240)
Cholelithiasis FREQUENT Cholelithiasis (HP:0001081)
Jaundice FREQUENT Jaundice (HP:0000952)
Endocrine 1
Delayed Puberty FREQUENT Delayed puberty (HP:0000823)
Head and Neck 1
Frontal Bossing FREQUENT Frontal bossing (HP:0002007)
Metabolism 1
Elevated Serum Ferritin VERY_FREQUENT Increased circulating ferritin concentration (HP:0003281)
Musculoskeletal 1
Osteoporosis FREQUENT Osteoporosis (HP:0000939)
Growth 1
Short Stature FREQUENT Short stature (HP:0004322)
🧬

Genetic Associations

4
HBB (Causative)
Autosomal recessive
Show evidence (1 reference)
PMID:20492708 SUPPORT Human Clinical
"Beta-thalassemias are caused by point mutations or, more rarely, deletions in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent (beta0) synthesis of the beta chains of hemoglobin (Hb). Transmission is autosomal recessive"
Confirms HBB mutations cause beta-thalassemia with autosomal recessive inheritance.
BCL11A (Modifier)
Show evidence (1 reference)
PMID:18691915 SUPPORT Human Clinical
"In this study, we showed that SNPs in BCL11A were associated with F-cell numbers in Chinese with beta-thalassemia trait, and with HbF levels in Thais with either beta-thalassemia or HbE trait and in African Americans with sickle cell anemia."
Supports BCL11A as an HbF modifier in beta-thalassemia populations.
KLF1 (Modifier)
HBS1L-MYB (Modifier)
💊

Treatments

8
Regular Red Blood Cell Transfusions
Action: blood transfusion MAXO:0000756
Mainstay of treatment for beta-thalassemia major. Regular transfusions maintain hemoglobin above 9-10 g/dL, suppressing ineffective erythropoiesis, preventing skeletal deformities, and allowing normal growth.
Iron Chelation Therapy
Action: iron chelation therapy Ontology label: chelator agent therapy MAXO:0001223
Essential to prevent iron overload from chronic transfusions. Agents include deferoxamine (subcutaneous/IV), deferasirox (oral), and deferiprone (oral). Cardiac T2* MRI guides chelation intensity.
Hydroxyurea
Action: chemotherapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: hydroxyurea ↗
Induces fetal hemoglobin production, beneficial in beta-thalassemia intermedia and as adjunct in thalassemia major to reduce transfusion requirements.
Splenectomy
Action: surgical procedure MAXO:0000004
Considered when hypersplenism increases transfusion requirements. Carries risk of post-splenectomy sepsis and thrombosis.
Allogeneic Hematopoietic Stem Cell Transplantation
Action: hematopoietic stem cell transplantation MAXO:0000747
Only established curative therapy. Best outcomes in young patients with HLA-matched sibling donors. Pesaro classification guides risk stratification.
Luspatercept
Action: Pharmacotherapy NCIT:C15986
Agent: luspatercept ↗
Recombinant fusion protein that promotes late-stage erythropoiesis by trapping TGF-beta superfamily ligands. Reduces transfusion burden in transfusion-dependent beta-thalassemia.
Show evidence (1 reference)
PMID:32212518 SUPPORT Human Clinical
"The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs...."
BELIEVE trial demonstrates luspatercept significantly reduces transfusion burden in transfusion-dependent beta-thalassemia.
Gene Therapy (Betibeglogene Autotemcel)
Action: gene therapy MAXO:0001001
Approved lentiviral gene therapy that adds functional copies of modified beta-globin gene to autologous hematopoietic stem cells. Can achieve transfusion independence in most patients.
Show evidence (1 reference)
PMID:34891223 SUPPORT Human Clinical
"Transfusion independence occurred in 20 of 22 patients who could be evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years of age."
Northstar-2 phase 3 trial demonstrates betibeglogene autotemcel achieves transfusion independence in 91% of evaluable patients.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Carrier screening and genetic counseling for at-risk populations. Prenatal diagnosis available via chorionic villus sampling.
🔬

Biochemical Markers

7
Hemoglobin (Decreased)
Context: Hemoglobin 3-7 g/dL in untreated thalassemia major
Pathograph Readouts
Readout Of Ineffective Erythropoiesis Negative Monitoring
Lower hemoglobin reflects the net anemia produced by ineffective erythropoiesis and hemolysis.
Show evidence (1 reference)
PMID:20492708 SUPPORT Human Clinical
"Individuals with thalassemia major usually present within the first two years of life with severe anemia, requiring regular red blood cell (RBC) transfusions."
This clinical review supports decreased hemoglobin/severe anemia as a key biochemical finding in beta-thalassemia major.
HbA2 (Elevated)
Context: Elevated to 3.5-7% in beta-thalassemia trait; diagnostic marker
Pathograph Readouts
Readout Of Defective Beta-Globin Synthesis Positive Diagnostic
Elevated HbA2 is a diagnostic readout of altered globin-chain production caused by beta-globin synthesis defects.
Show evidence (1 reference)
PMID:7653059 SUPPORT Human Clinical
"The increased level of HbA2 is a reliable marker of heterozygous beta-thalassaemia."
This diagnostic study supports elevated HbA2 as a marker for beta-thalassemia heterozygosity.
HbF (Elevated)
Context: Variably elevated depending on genotype and modifiers
Pathograph Readouts
Readout Of Fetal Hemoglobin Modulation Positive Monitoring
HbF level reports fetal-hemoglobin persistence or induction and modifies the clinical impact of beta-globin deficiency.
Show evidence (1 reference)
PMID:15163316 SUPPORT Human Clinical
"The results indicated that F-RBC were more numerous in beta-thalassemic (both transfused and nontransfused) patients than in normal donors, but, in most cases, their HbF content was comparable, suggesting that increased HbF in thalassemia is mainly due to higher %F-cells rather than an increased..."
This flow-cytometry study supports elevated HbF-containing red cells as a beta-thalassemia biochemical finding.
Serum Ferritin (Elevated)
Context: Reflects iron overload from transfusions and increased absorption
Pathograph Readouts
Readout Of Iron Overload Positive Monitoring
Higher serum ferritin is a blood readout of systemic iron burden, though inflammation and liver injury can affect interpretation.
Serum ferritin and liver iron concentration
Traditional Validated Surrogate Endpoint
Patients with chronic iron overload or non-transfusion-dependent thalassemia syndromes
Serum ferritin and liver iron concentration
Traditional Validated Surrogate Endpoint
2 years or older for chronic iron overload and 10 years older for non-transfusion-dependent thalassemia syndromes
Show evidence (1 reference)
PMID:24790662 SUPPORT Human Clinical
"Iron overload can be determined by serum ferritin measurement."
This beta-thalassemia major/intermedia study supports serum ferritin as a biochemical marker of iron overload.
Indirect Bilirubin (Elevated)
Context: From chronic hemolysis
Pathograph Readouts
Readout Of Chronic Hemolysis Positive Monitoring
Indirect bilirubin elevation reflects heme catabolism from chronic red-cell destruction.
Show evidence (1 reference)
PMID:20492708 PARTIAL Human Clinical
"Findings in untreated or poorly transfused individuals with thalassemia major, as seen in some developing countries, are growth retardation, pallor, jaundice, poor musculature, hepatosplenomegaly, leg ulcers, development of masses from extramedullary hematopoiesis, and skeletal changes that..."
The review supports jaundice in untreated/poorly transfused thalassemia major, which is consistent with bilirubin elevation but does not directly measure indirect bilirubin.
Reticulocytes (Variable)
Context: Elevated but inappropriately low for degree of anemia
Pathograph Readouts
Correlates With Ineffective Erythropoiesis Threshold Dependent Monitoring
Reticulocyte counts reflect marrow output but are interpreted relative to the severity of anemia and ineffective erythropoiesis.
Show evidence (1 reference)
PMID:15163316 SUPPORT Human Clinical
"Using flow cytometry, we studied the percentage of HbF-containing cells and their HbF content in RBC, reticulocytes (retics) and normoblasts (NRBC) present in the peripheral blood of patients with beta-thalassemia."
This study supports reticulocytes as a measured peripheral-blood cell population in beta-thalassemia biomarker assessment.
Liver Iron Concentration (Elevated)
Context: MRI- or biopsy-derived tissue iron burden, especially relevant in transfusion-dependent or iron-overloaded beta-thalassemia.
Pathograph Readouts
Readout Of Iron Overload Positive Monitoring
Liver iron concentration is a tissue-level readout of iron overload and complements serum ferritin for chelation monitoring.
Serum ferritin and liver iron concentration
Traditional Validated Surrogate Endpoint
Patients with chronic iron overload or non-transfusion-dependent thalassemia syndromes
Serum ferritin and liver iron concentration
Traditional Validated Surrogate Endpoint
2 years or older for chronic iron overload and 10 years older for non-transfusion-dependent thalassemia syndromes
Show evidence (1 reference)
PMID:30588469 SUPPORT Human Clinical
"Correlations of LIC, as determined by R2-MRI, with SF and ALT levels, were assessed in all participants."
This thalassemia intermedia study supports R2-MRI liver iron concentration as a measured tissue biomarker for iron overload.
{ }

Source YAML

click to show 
name: Beta Thalassemia
category: Mendelian
parents:
- Hematological Disease
- Genetic Disease
disease_term:
  preferred_term: beta thalassemia
  term:
    id: MONDO:0019402
    label: beta thalassemia
has_subtypes:
- name: Beta Thalassemia Minor (Trait)
  description: >
    Heterozygous carriers with one normal and one affected HBB allele.
    Usually asymptomatic or mild microcytic anemia. Identified by elevated HbA2.
- name: Beta Thalassemia Intermedia
  description: >
    Moderate disease severity, typically homozygous or compound heterozygous
    for mild HBB mutations. Patients may require intermittent transfusions.
- name: Beta Thalassemia Major (Cooley Anemia)
  description: >
    Severe transfusion-dependent anemia due to homozygous or compound
    heterozygous severe HBB mutations. Presents in first 1-2 years of life.
prevalence:
- population: Global carriers
  percentage: 1.5
  notes: >
    Estimated 1.5% of the global population are heterozygous carriers.
    Highest prevalence occurs in the Mediterranean basin, Middle East,
    Indian subcontinent, Southeast Asia, and Melanesia.
  evidence:
  - reference: PMID:28293406
    reference_title: "β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 1.5% of the global population are heterozygotes (carriers) of the β-thalassemias; there is a high incidence in populations from the Mediterranean basin, throughout the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia to the Pacific Islands."
    explanation: Supports the stated global carrier prevalence and its geographic concentration.
inheritance:
- name: Autosomal recessive
pathophysiology:
- name: Defective Beta-Globin Synthesis
  description: >
    Mutations in the HBB gene reduce or abolish beta-globin chain production.
    Beta-zero (beta0) mutations produce no beta-globin; beta-plus (beta+)
    mutations produce reduced amounts. Over 300 mutations have been identified,
    including point mutations, small deletions, and rarely large deletions.
  genes:
  - preferred_term: HBB
    term:
      id: hgnc:4827
      label: HBB
  biological_processes:
  - preferred_term: hemoglobin biosynthetic process
    modifier: DECREASED
    term:
      id: GO:0042541
      label: hemoglobin biosynthetic process
  cell_types:
  - preferred_term: erythroblast
    term:
      id: CL:0000765
      label: erythroblast
  downstream:
  - target: Alpha-Globin Chain Excess
    description: >
      Reduced beta-globin leads to unpaired alpha-globin chains that
      precipitate and damage erythroid precursors.
  evidence:
  - reference: PMID:20492708
    reference_title: "Beta-thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Beta-thalassemias are caused by point mutations or, more rarely, deletions in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent (beta0) synthesis of the beta chains of hemoglobin (Hb)."
    explanation: Confirms that HBB mutations lead to reduced or absent beta-globin chain synthesis.
- name: Alpha-Globin Chain Excess
  description: >
    Excess unpaired alpha-globin chains precipitate as insoluble aggregates
    in erythroid precursors, causing oxidative membrane damage, apoptosis
    of erythroblasts (ineffective erythropoiesis), and shortened survival
    of mature red blood cells (hemolysis). This is the central pathogenic
    mechanism distinguishing beta-thalassemia from alpha-thalassemia.
  genes:
  - preferred_term: HBA1
    term:
      id: hgnc:4823
      label: HBA1
  - preferred_term: HBA2
    term:
      id: hgnc:4824
      label: HBA2
  biological_processes:
  - preferred_term: response to oxidative stress
    modifier: INCREASED
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  cell_types:
  - preferred_term: erythroblast
    term:
      id: CL:0000765
      label: erythroblast
  downstream:
  - target: Ineffective Erythropoiesis
    description: >
      Apoptosis of alpha-chain-laden erythroid precursors in the bone marrow.
  - target: Chronic Hemolysis
    description: >
      Surviving erythrocytes with membrane damage are cleared prematurely.
  evidence:
  - reference: PMID:21705976
    reference_title: "Pathophysiology of beta thalassaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "unbalanced alpha globin chain synthesis results in severely rheologically compromised erythrocytes with premature destruction in the peripheral circulation and ineffective erythropoiesis within the bone marrow and in extramedullary sites"
    explanation: Confirms that excess alpha-globin chains cause both peripheral erythrocyte destruction and ineffective erythropoiesis.
- name: Ineffective Erythropoiesis
  description: >
    Massive expansion of erythroid precursors in bone marrow and
    extramedullary sites, but most cells undergo apoptosis before
    maturing. This drives erythroid hyperplasia, skeletal deformities
    (marrow expansion), and inappropriately low reticulocyte output
    relative to the degree of erythroid expansion.
  biological_processes:
  - preferred_term: erythrocyte differentiation
    modifier: ABNORMAL
    term:
      id: GO:0030218
      label: erythrocyte differentiation
  - preferred_term: erythrocyte homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0034101
      label: erythrocyte homeostasis
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  downstream:
  - target: Iron Overload
    description: >
      Ineffective erythropoiesis suppresses hepcidin, increasing
      intestinal iron absorption and leading to iron overload even
      without transfusions.
  evidence:
  - reference: PMID:22631035
    reference_title: "The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ineffective erythropoiesis is the hallmark of beta-thalassemia that triggers a cascade of compensatory mechanisms resulting in clinical sequelae such as erythroid marrow expansion, extramedullary hematopoiesis, splenomegaly, and increased gastrointestinal iron absorption."
    explanation: Confirms ineffective erythropoiesis as the hallmark mechanism driving marrow expansion, extramedullary hematopoiesis, and iron absorption.
- name: Chronic Hemolysis
  description: >
    Peripheral destruction of abnormal erythrocytes with membrane damage
    from precipitated alpha-globin chains. Leads to anemia, jaundice,
    splenomegaly, and gallstones.
  biological_processes:
  - preferred_term: erythrocyte homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0034101
      label: erythrocyte homeostasis
  - preferred_term: positive regulation of erythrocyte clearance
    modifier: INCREASED
    term:
      id: GO:0034108
      label: positive regulation of erythrocyte clearance
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Iron Overload
    description: Iron released from hemolyzed red cells contributes to iron loading.
  evidence:
  - reference: PMID:21705976
    reference_title: "Pathophysiology of beta thalassaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "unbalanced alpha globin chain synthesis results in severely rheologically compromised erythrocytes with premature destruction in the peripheral circulation"
    explanation: Confirms peripheral destruction of rheologically compromised erythrocytes (hemolysis).
- name: Iron Overload
  description: >
    Iron accumulation from transfusional hemosiderosis and increased
    intestinal absorption (due to hepcidin suppression from ineffective
    erythropoiesis). Iron deposits in heart, liver, and endocrine organs
    cause cardiomyopathy, liver fibrosis, diabetes, and hypogonadism.
  genes:
  - preferred_term: HAMP
    term:
      id: hgnc:15598
      label: HAMP
  biological_processes:
  - preferred_term: intracellular iron ion homeostasis
    modifier: ABNORMAL
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
  - preferred_term: iron ion transport
    modifier: INCREASED
    term:
      id: GO:0006826
      label: iron ion transport
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:21705976
    reference_title: "Pathophysiology of beta thalassaemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "erythropoiesis,anemia and hypoxia down-regulate hepcidin, the master regulator of iron homeostasis. Hepcidin deficiency in turn allows excessive duodenal iron absorption and development of systemic iron overload."
    explanation: Confirms hepcidin suppression from ineffective erythropoiesis as the mechanism of iron overload.
  - reference: PMID:20492708
    reference_title: "Beta-thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regular transfusion therapy leads to iron overload-related complications including endocrine complication (growth retardation, failure of sexual maturation, diabetes mellitus, and insufficiency of the parathyroid, thyroid, pituitary, and less commonly, adrenal glands), dilated myocardiopathy, liver fibrosis and cirrhosis)"
    explanation: Confirms iron overload complications affecting heart, liver, and endocrine organs.
- name: Fetal Hemoglobin Modulation
  description: >
    Genetic modifiers that increase fetal hemoglobin (HbF) production
    ameliorate disease severity by compensating for deficient adult
    hemoglobin (HbA) and reducing free alpha-globin chains. Key modifiers
    include BCL11A, HBS1L-MYB locus, and KLF1.
  genes:
  - preferred_term: BCL11A
    term:
      id: hgnc:13221
      label: BCL11A
  - preferred_term: KLF1
    term:
      id: hgnc:6345
      label: KLF1
  - preferred_term: MYB
    term:
      id: hgnc:7545
      label: MYB
  - preferred_term: HBS1L
    term:
      id: hgnc:4834
      label: HBS1L
  biological_processes:
  - preferred_term: regulation of hemoglobin biosynthetic process
    term:
      id: GO:0046984
      label: regulation of hemoglobin biosynthetic process
  cell_types:
  - preferred_term: erythroid progenitor cell
    term:
      id: CL:0000038
      label: erythroid progenitor cell
  evidence:
  - reference: PMID:18691915
    reference_title: "BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we showed that SNPs in BCL11A were associated with F-cell numbers in Chinese with beta-thalassemia trait, and with HbF levels in Thais with either beta-thalassemia or HbE trait and in African Americans with sickle cell anemia."
    explanation: Provides beta-thalassemia-specific evidence that BCL11A variants modulate HbF-related traits.
phenotypes:
- category: Hematological
  name: Microcytic Hypochromic Anemia
  description: >
    Severe anemia with reduced MCV and MCH due to deficient hemoglobin
    synthesis. Hemoglobin levels can fall to 3-7 g/dL in untreated
    beta-thalassemia major.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: hypochromic microcytic anemia
    term:
      id: HP:0004840
      label: Hypochromic microcytic anemia
  evidence:
  - reference: PMID:20492708
    reference_title: "Beta-thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with thalassemia major usually present within the first two years of life with severe anemia, requiring regular red blood cell (RBC) transfusions."
    explanation: Confirms severe anemia as the defining presentation of thalassemia major.
- category: Hematological
  name: Decreased Mean Corpuscular Volume
  description: >
    MCV typically 55-75 fL in beta-thalassemia trait and even lower
    in thalassemia major.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: decreased mean corpuscular volume
    term:
      id: HP:0025066
      label: Decreased mean corpuscular volume
- category: Hematological
  name: Reticulocytosis
  description: >
    Elevated reticulocyte count reflecting compensatory erythropoietic
    drive, though inappropriately low relative to degree of anemia
    due to ineffective erythropoiesis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: reticulocytosis
    term:
      id: HP:0001923
      label: Reticulocytosis
- category: Hematological
  name: Erythroid Hyperplasia
  description: >
    Massively expanded erythroid compartment in bone marrow (erythroid
    to myeloid ratio may exceed 1:1) as a compensatory response.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: erythroid hyperplasia
    term:
      id: HP:0012132
      label: Erythroid hyperplasia
- category: Hematological
  name: Persistence of Hemoglobin F
  description: >
    Elevated fetal hemoglobin as a compensatory mechanism. HbF levels
    vary widely depending on genetic modifiers.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: persistence of hemoglobin F
    term:
      id: HP:0011904
      label: Persistence of hemoglobin F
- category: Hematological
  name: Target Cells
  description: >
    Target cells (codocytes) on peripheral blood smear due to
    reduced hemoglobin content and relative membrane excess.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: target cells
    term:
      id: HP:0034280
      label: Target cells
- category: Hematological
  name: Extramedullary Hematopoiesis
  description: >
    Compensatory hematopoiesis in liver, spleen, and paravertebral
    regions due to insufficient bone marrow output.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: extramedullary hematopoiesis
    term:
      id: HP:0001978
      label: Extramedullary hematopoiesis
- category: Gastrointestinal
  name: Splenomegaly
  description: >
    Splenic enlargement from extramedullary hematopoiesis and
    increased erythrocyte destruction.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
- category: Gastrointestinal
  name: Hepatomegaly
  description: >
    Liver enlargement from extramedullary hematopoiesis, iron
    deposition, and chronic hemolysis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Gastrointestinal
  name: Cholelithiasis
  description: >
    Pigment gallstones from chronic bilirubin overproduction
    secondary to hemolysis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: cholelithiasis
    term:
      id: HP:0001081
      label: Cholelithiasis
- category: Metabolic
  name: Jaundice
  description: >
    Unconjugated hyperbilirubinemia from chronic hemolysis.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: jaundice
    term:
      id: HP:0000952
      label: Jaundice
- category: Metabolic
  name: Elevated Serum Ferritin
  description: >
    Increased serum ferritin reflecting tissue iron deposition from
    transfusions and increased intestinal absorption.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: increased circulating ferritin concentration
    term:
      id: HP:0003281
      label: Increased circulating ferritin concentration
- category: Cardiovascular
  name: Cardiomyopathy
  description: >
    Iron-mediated cardiac damage is the leading cause of death in
    transfusion-dependent beta-thalassemia. Manifests as dilated
    cardiomyopathy and heart failure.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
- category: Cardiovascular
  name: Pulmonary Hypertension
  description: >
    Chronic hemolysis depletes nitric oxide, promoting pulmonary
    vasoconstriction and remodeling. Etiology in thalassemia is
    often mixed (pre- and post-capillary).
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: elevated pulmonary artery pressure
    term:
      id: HP:0004890
      label: Elevated pulmonary artery pressure
- category: Skeletal
  name: Frontal Bossing
  description: >
    Skeletal deformity from marrow expansion in flat bones of the
    skull. Classic finding in undertreated thalassemia major.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
- category: Skeletal
  name: Osteoporosis
  description: >
    Reduced bone mineral density from marrow expansion, iron
    overload effects on bone, and endocrine dysfunction.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
- category: Growth
  name: Short Stature
  description: >
    Growth retardation from chronic anemia, iron overload-related
    endocrinopathies, and chelation therapy effects.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: short stature
    term:
      id: HP:0004322
      label: Short stature
- category: Endocrine
  name: Delayed Puberty
  description: >
    Hypogonadotropic hypogonadism from iron deposition in the
    pituitary and gonads.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: delayed puberty
    term:
      id: HP:0000823
      label: Delayed puberty
biochemical:
- name: Hemoglobin
  presence: Decreased
  context: Hemoglobin 3-7 g/dL in untreated thalassemia major
  readouts:
  - target: Ineffective Erythropoiesis
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: MONITORING
    interpretation: >-
      Lower hemoglobin reflects the net anemia produced by ineffective
      erythropoiesis and hemolysis.
  biomarker_term:
    preferred_term: hemoglobin measurement
    term:
      id: NCIT:C64848
      label: Hemoglobin Measurement
  evidence:
  - reference: PMID:20492708
    reference_title: "Beta-thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with thalassemia major usually present within the first two
      years of life with severe anemia, requiring regular red blood cell (RBC)
      transfusions.
    explanation: >-
      This clinical review supports decreased hemoglobin/severe anemia as a key
      biochemical finding in beta-thalassemia major.
- name: HbA2
  presence: Elevated
  context: Elevated to 3.5-7% in beta-thalassemia trait; diagnostic marker
  readouts:
  - target: Defective Beta-Globin Synthesis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Elevated HbA2 is a diagnostic readout of altered globin-chain production
      caused by beta-globin synthesis defects.
  biomarker_term:
    preferred_term: hemoglobin A2 measurement
    term:
      id: NCIT:C92259
      label: Hemoglobin A2 Measurement
  evidence:
  - reference: PMID:7653059
    reference_title: "[Diagnosis of beta-thalassemia on the basis of HbA2 determination]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The increased level of HbA2 is a reliable marker of heterozygous
      beta-thalassaemia.
    explanation: >-
      This diagnostic study supports elevated HbA2 as a marker for
      beta-thalassemia heterozygosity.
- name: HbF
  presence: Elevated
  context: Variably elevated depending on genotype and modifiers
  readouts:
  - target: Fetal Hemoglobin Modulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      HbF level reports fetal-hemoglobin persistence or induction and modifies
      the clinical impact of beta-globin deficiency.
  biomarker_term:
    preferred_term: hemoglobin F measurement
    term:
      id: NCIT:C92262
      label: Hemoglobin F Measurement
  evidence:
  - reference: PMID:15163316
    reference_title: "Flow cytometric analysis of fetal hemoglobin in erythroid precursors of beta-thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results indicated that F-RBC were more numerous in beta-thalassemic
      (both transfused and nontransfused) patients than in normal donors, but,
      in most cases, their HbF content was comparable, suggesting that increased
      HbF in thalassemia is mainly due to higher %F-cells rather than an
      increased HbF per cell.
    explanation: >-
      This flow-cytometry study supports elevated HbF-containing red cells as a
      beta-thalassemia biochemical finding.
- name: Serum Ferritin
  presence: Elevated
  context: Reflects iron overload from transfusions and increased absorption
  readouts:
  - target: Iron Overload
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-073
    - FDA-SE-pediatric-noncancer-051
    interpretation: >-
      Higher serum ferritin is a blood readout of systemic iron burden, though
      inflammation and liver injury can affect interpretation.
  biomarker_term:
    preferred_term: serum ferritin
    term:
      id: NCIT:C224202
      label: Serum Ferritin
  evidence:
  - reference: PMID:24790662
    reference_title: "Iron overload in Beta thalassaemia major and intermedia patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Iron overload can be determined by serum ferritin measurement.
    explanation: >-
      This beta-thalassemia major/intermedia study supports serum ferritin as a
      biochemical marker of iron overload.
- name: Indirect Bilirubin
  presence: Elevated
  context: From chronic hemolysis
  readouts:
  - target: Chronic Hemolysis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >-
      Indirect bilirubin elevation reflects heme catabolism from chronic
      red-cell destruction.
  biomarker_term:
    preferred_term: indirect bilirubin measurement
    term:
      id: NCIT:C64483
      label: Indirect Bilirubin Measurement
  evidence:
  - reference: PMID:20492708
    reference_title: "Beta-thalassemia."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Findings in untreated or poorly transfused individuals with thalassemia
      major, as seen in some developing countries, are growth retardation,
      pallor, jaundice, poor musculature, hepatosplenomegaly, leg ulcers,
      development of masses from extramedullary hematopoiesis, and skeletal
      changes that result from expansion of the bone marrow.
    explanation: >-
      The review supports jaundice in untreated/poorly transfused thalassemia
      major, which is consistent with bilirubin elevation but does not directly
      measure indirect bilirubin.
- name: Reticulocytes
  presence: Variable
  context: Elevated but inappropriately low for degree of anemia
  readouts:
  - target: Ineffective Erythropoiesis
    relationship: CORRELATES_WITH
    direction: THRESHOLD_DEPENDENT
    endpoint_context: MONITORING
    interpretation: >-
      Reticulocyte counts reflect marrow output but are interpreted relative to
      the severity of anemia and ineffective erythropoiesis.
  biomarker_term:
    preferred_term: reticulocyte count
    term:
      id: NCIT:C51947
      label: Reticulocyte Count
  evidence:
  - reference: PMID:15163316
    reference_title: "Flow cytometric analysis of fetal hemoglobin in erythroid precursors of beta-thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using flow cytometry, we studied the percentage of HbF-containing cells
      and their HbF content in RBC, reticulocytes (retics) and normoblasts
      (NRBC) present in the peripheral blood of patients with beta-thalassemia.
    explanation: >-
      This study supports reticulocytes as a measured peripheral-blood cell
      population in beta-thalassemia biomarker assessment.
- name: Liver Iron Concentration
  presence: Elevated
  context: >-
    MRI- or biopsy-derived tissue iron burden, especially relevant in
    transfusion-dependent or iron-overloaded beta-thalassemia.
  readouts:
  - target: Iron Overload
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-073
    - FDA-SE-pediatric-noncancer-051
    interpretation: >-
      Liver iron concentration is a tissue-level readout of iron overload and
      complements serum ferritin for chelation monitoring.
  biomarker_term:
    preferred_term: liver iron concentration
    term:
      id: NCIT:C124065
      label: Liver Iron Concentration
  synonyms:
  - LIC
  evidence:
  - reference: PMID:30588469
    reference_title: "Relationship between liver iron concentration determined by R2-MRI, serum ferritin, and liver enzymes in patients with thalassemia intermedia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Correlations of LIC, as determined by R2-MRI, with SF and ALT levels,
      were assessed in all participants.
    explanation: >-
      This thalassemia intermedia study supports R2-MRI liver iron
      concentration as a measured tissue biomarker for iron overload.
genetic:
- name: HBB
  association: Causative
  inheritance:
  - name: Autosomal recessive
  notes: >
    Over 300 mutations in the HBB gene cause beta-thalassemia.
    Beta-zero mutations (e.g., codon 39 C>T, IVS-I-1 G>A) abolish
    beta-globin production. Beta-plus mutations (e.g., IVS-I-110 G>A,
    -28 A>G) reduce production.
  evidence:
  - reference: PMID:20492708
    reference_title: "Beta-thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Beta-thalassemias are caused by point mutations or, more rarely, deletions in the beta globin gene on chromosome 11, leading to reduced (beta+) or absent (beta0) synthesis of the beta chains of hemoglobin (Hb). Transmission is autosomal recessive"
    explanation: Confirms HBB mutations cause beta-thalassemia with autosomal recessive inheritance.
- name: BCL11A
  association: Modifier
  notes: >
    Genetic variants in BCL11A modulate HbF levels and disease severity.
    BCL11A is the major silencer of gamma-globin expression in adult
    erythroid cells.
  evidence:
  - reference: PMID:18691915
    reference_title: "BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we showed that SNPs in BCL11A were associated with F-cell numbers in Chinese with beta-thalassemia trait, and with HbF levels in Thais with either beta-thalassemia or HbE trait and in African Americans with sickle cell anemia."
    explanation: Supports BCL11A as an HbF modifier in beta-thalassemia populations.
- name: KLF1
  association: Modifier
  notes: >
    KLF1 (EKLF) mutations can increase HbF levels by reducing BCL11A
    expression. KLF1 haploinsufficiency ameliorates beta-thalassemia
    severity.
- name: HBS1L-MYB
  association: Modifier
  notes: >
    Variants in the HBS1L-MYB intergenic region on chromosome 6q23
    are the second major GWAS locus for HbF levels.
treatments:
- name: Regular Red Blood Cell Transfusions
  description: >
    Mainstay of treatment for beta-thalassemia major. Regular
    transfusions maintain hemoglobin above 9-10 g/dL, suppressing
    ineffective erythropoiesis, preventing skeletal deformities,
    and allowing normal growth.
  treatment_term:
    preferred_term: blood transfusion
    term:
      id: MAXO:0000756
      label: blood transfusion
- name: Iron Chelation Therapy
  description: >
    Essential to prevent iron overload from chronic transfusions.
    Agents include deferoxamine (subcutaneous/IV), deferasirox (oral),
    and deferiprone (oral). Cardiac T2* MRI guides chelation intensity.
  treatment_term:
    preferred_term: iron chelation therapy
    term:
      id: MAXO:0001223
      label: chelator agent therapy
- name: Hydroxyurea
  description: >
    Induces fetal hemoglobin production, beneficial in beta-thalassemia
    intermedia and as adjunct in thalassemia major to reduce transfusion
    requirements.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: hydroxyurea
      term:
        id: CHEBI:44423
        label: hydroxyurea
- name: Splenectomy
  description: >
    Considered when hypersplenism increases transfusion requirements.
    Carries risk of post-splenectomy sepsis and thrombosis.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  description: >
    Only established curative therapy. Best outcomes in young patients
    with HLA-matched sibling donors. Pesaro classification guides
    risk stratification.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: MAXO:0000747
      label: hematopoietic stem cell transplantation
- name: Luspatercept
  description: >
    Recombinant fusion protein that promotes late-stage erythropoiesis
    by trapping TGF-beta superfamily ligands. Reduces transfusion
    burden in transfusion-dependent beta-thalassemia.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: luspatercept
      term:
        id: NCIT:C104012
        label: Luspatercept
  evidence:
  - reference: PMID:32212518
    reference_title: "A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P<0.001)."
    explanation: BELIEVE trial demonstrates luspatercept significantly reduces transfusion burden in transfusion-dependent beta-thalassemia.
- name: Gene Therapy (Betibeglogene Autotemcel)
  description: >
    Approved lentiviral gene therapy that adds functional copies of
    modified beta-globin gene to autologous hematopoietic stem cells.
    Can achieve transfusion independence in most patients.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  evidence:
  - reference: PMID:34891223
    reference_title: "Betibeglogene Autotemcel Gene Therapy for Non-β(0)/β(0) Genotype β-Thalassemia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transfusion independence occurred in 20 of 22 patients who could be evaluated (91%), including 6 of 7 patients (86%) who were younger than 12 years of age."
    explanation: Northstar-2 phase 3 trial demonstrates betibeglogene autotemcel achieves transfusion independence in 91% of evaluable patients.
- name: Genetic Counseling
  description: >
    Carrier screening and genetic counseling for at-risk populations.
    Prenatal diagnosis available via chorionic villus sampling.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
references:
- reference: DOI:10.1038/s41467-023-41961-9
  title: Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype
  findings: []
- reference: DOI:10.1182/bloodadvances.2022007655
  title: Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis
  findings: []
- reference: DOI:10.1182/bloodadvances.2023012010
  title: A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice
  findings: []
- reference: DOI:10.14218/ge.2023.00128
  title: 'Exploring the Impact of Iron Overload on Mitochondrial DNA in β-Thalassemia: A Comprehensive Review'
  findings: []
- reference: DOI:10.3324/haematol.2023.283057
  title: Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis
  findings: []
- reference: DOI:10.3389/fmolb.2023.1248742
  title: A randomized placebo−controlled clinical trial of oral green tea epigallocatechin 3−gallate on erythropoiesis and oxidative stress in transfusion−dependent β−thalassemia patients
  findings: []
- reference: DOI:10.3389/fphys.2024.1346173
  title: The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia
  findings: []
- reference: DOI:10.3390/cells13110918
  title: Therapeutic Relevance of Inducing Autophagy in β-Thalassemia
  findings: []
- reference: DOI:10.3390/ijms24043995
  title: Managing the Dual Nature of Iron to Preserve Health
  findings: []
- reference: DOI:10.3390/ijms25063400
  title: 'Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management'
  findings: []
- reference: DOI:10.3390/thalassrep13030017
  title: 'Understanding the Intricacies of Iron Overload Associated with β-Thalassemia: A Comprehensive Review'
  findings: []
- reference: DOI:10.3390/thalassrep14040010
  title: 'Thalassemia: Pathophysiology, Diagnosis, and Advances in Treatment'
  findings: []
updated_date: '2026-05-10T22:52:07Z'
📚

References & Deep Research

References

12
DOI:10.1038/s41467-023-41961-9
Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype
No top-level findings curated for this source.
DOI:10.1182/bloodadvances.2022007655
Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis
No top-level findings curated for this source.
DOI:10.1182/bloodadvances.2023012010
A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice
No top-level findings curated for this source.
DOI:10.14218/ge.2023.00128
Exploring the Impact of Iron Overload on Mitochondrial DNA in β-Thalassemia: A Comprehensive Review
No top-level findings curated for this source.
DOI:10.3324/haematol.2023.283057
Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis
No top-level findings curated for this source.
DOI:10.3389/fmolb.2023.1248742
A randomized placebo−controlled clinical trial of oral green tea epigallocatechin 3−gallate on erythropoiesis and oxidative stress in transfusion−dependent β−thalassemia patients
No top-level findings curated for this source.
DOI:10.3389/fphys.2024.1346173
The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia
No top-level findings curated for this source.
DOI:10.3390/cells13110918
Therapeutic Relevance of Inducing Autophagy in β-Thalassemia
No top-level findings curated for this source.
DOI:10.3390/ijms24043995
Managing the Dual Nature of Iron to Preserve Health
No top-level findings curated for this source.
DOI:10.3390/ijms25063400
Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management
No top-level findings curated for this source.
DOI:10.3390/thalassrep13030017
Understanding the Intricacies of Iron Overload Associated with β-Thalassemia: A Comprehensive Review
No top-level findings curated for this source.
DOI:10.3390/thalassrep14040010
Thalassemia: Pathophysiology, Diagnosis, and Advances in Treatment
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Beta Thalassemia
  • Category: Mendelian
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 25

Key Pathophysiology Nodes

  • Defective Beta-Globin Synthesis
  • Alpha-Globin Chain Excess
  • Ineffective Erythropoiesis
  • Chronic Hemolysis
  • Iron Overload
  • Fetal Hemoglobin Modulation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1038/s41467-023-41961-9
  • DOI:10.1182/bloodadvances.2022007655
  • DOI:10.1182/bloodadvances.2023012010
  • DOI:10.14218/ge.2023.00128
  • DOI:10.3324/haematol.2023.283057
  • DOI:10.3389/fmolb.2023.1248742
  • DOI:10.3389/fphys.2024.1346173
  • DOI:10.3390/cells13110918
  • DOI:10.3390/ijms24043995
  • DOI:10.3390/ijms25063400
  • DOI:10.3390/thalassrep13030017
  • DOI:10.3390/thalassrep14040010
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 34 citations 2026-02-15T19:56:54.289180

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Beta Thalassemia
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Beta Thalassemia. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Beta thalassemia (β-thalassemia): pathophysiology research report (molecular/cellular focus)

Target disease and identifiers

  • Disease: β-thalassemia (Mendelian hemoglobinopathy; β-globin quantitative defect). Core molecular defect is reduced/absent β-globin production, typically due to HBB variants (HGNC:HBB). (liang2023elevatedcdkn1a(p21) pages 1-2, daniels2023humancellularmodel pages 1-2)
  • Disease subtypes (pathophysiology relevant): transfusion-dependent thalassemia (TDT) vs non-transfusion-dependent thalassemia (NTDT), reflecting severity of ineffective erythropoiesis and anemia. (basu2023understandingtheintricacies pages 1-2, traegersynodinos2024impactofαglobin pages 1-2)

1) Key concepts and definitions (current understanding)

1.1 Core definition: globin chain imbalance → ineffective erythropoiesis

β-thalassemia is defined by reduced (β+) or absent (β0) β-globin chain synthesis, producing α/non-α globin chain imbalance and impaired hemoglobin A (HbA; α2β2) formation. (liang2023elevatedcdkn1a(p21) pages 1-2, daniels2023humancellularmodel pages 1-2)

A central mechanistic concept is that reduced β-globin causes excess free α-globin, which forms insoluble aggregates and undergoes auto-oxidation, generating ROS and triggering intracellular injury that culminates in ineffective erythropoiesis (IE) (intramedullary death of erythroid precursors) and peripheral hemolysis. Nature Communications describes this as: “Reduction in β-globin results in excess α-globin, forming insoluble aggregates which undergo auto-oxidation leading to increased reactive oxygen species (ROS) and a range of intracellular downstream events that result in ineffective erythropoiesis (IE), the hallmark and primary cause of β-thalassemia disease pathophysiology.” (daniels2023humancellularmodel pages 1-2)

Traeger‑Synodinos et al. emphasize the specific toxicity of α-globin excess: “Free α-globin chains cannot form homo-tetramers, as they are highly unstable and tend to aggregate, forming insoluble precipitates in the cell. The reactive oxygen species (ROS) formed as a result, underlie red cell membrane damage, ultimately causing premature cell death, observed as ineffective erythropoiesis.” (traegersynodinos2024impactofαglobin pages 1-2)

1.2 Distinguishing pathophysiologic modules

The modern mechanistic view is modular: 1. Erythroid module: globin imbalance → oxidative injury → apoptosis/eryptosis → maturation block and IE. (daniels2023humancellularmodel pages 1-2, liang2023elevatedcdkn1a(p21) pages 1-2) 2. Iron homeostasis module: IE and anemia-driven erythropoietic stress suppress hepcidin, increasing intestinal iron absorption and mobilization of iron from stores, predisposing to iron overload (particularly with transfusion). (wake2024ahumanantimatriptase2 pages 9-10, guerra2023novelpotentialtherapeutics pages 1-3) 3. End-organ damage module: iron excess → NTBI, ROS, mitochondrial dysfunction → liver/cardiac/endocrine toxicity. (narahari2024exploringtheimpact pages 1-2)

2) Core pathophysiology (mechanisms, pathways, cellular processes)

2.1 Primary pathophysiologic mechanisms

(A) α-globin precipitation and oxidative damage

In β-thalassemia, “excess unpaired alpha chains precipitate as hemochromes, leading to the premature death of erythroid precursor cells and impaired erythropoiesis.” (narahari2024exploringtheimpact pages 1-2)

(B) Ineffective erythropoiesis and maturation arrest

IE features expansion of erythroid progenitors but failure to produce mature RBCs. Daniels et al. specify a stage: IE “is manifest as increased expansion of erythroid progenitors… but with a maturation block at the polychromatic stage of differentiation… with increased apoptosis.” (daniels2023humancellularmodel pages 1-2)

(C) Apoptosis networks in erythroid precursors (FOXO3–P21 axis)

A 2023 Blood Advances study frames β-thalassemia as a disorder where “Premature death of β-thalassemic erythroid precursors results in ineffective erythroid maturation, increased production of erythropoietin (EPO), expansion of erythroid progenitor compartment, extramedullary erythropoiesis, and splenomegaly.” (liang2023elevatedcdkn1a(p21) pages 1-2)

Mechanistically, Liang et al. describe globin imbalance→redox injury→aggregates: “The accumulation of excessive unpaired α-globin chains in erythroblasts triggers redox-mediated reactions, leading to the generation of toxic aggregates… [resulting in] premature death, ineffective erythroid maturation, and hemolytic anemia.” (liang2023elevatedcdkn1a(p21) pages 1-2)

They also provide experimental support that FOXO3 and its target CDKN1A/p21 regulate apoptosis in β-thalassemic erythroid cells, showing reduced apoptosis in genetic knockouts while IE may persist. (liang2023elevatedcdkn1a(p21) pages 1-2, liang2023elevatedcdkn1a(p21) pages 6-7)

2.2 Dysregulated iron homeostasis pathways (hepcidin/ferroportin axis)

(A) Hepcidin as the systemic “master regulator”

Guerra et al. summarize the canonical axis: hepcidin (HAMP) from liver binds/inhibits ferroportin (SLC40A1) to limit iron export from enterocytes, macrophages, and hepatocytes; high hepcidin → iron-restricted erythropoiesis/anemia, low hepcidin → iron overload. (guerra2023novelpotentialtherapeutics pages 1-3)

(B) Hepatic BMP–SMAD control of hepcidin and its negative regulation by TMPRSS6

Hepcidin transcription is driven by a hepatic BMP–SMAD pathway. Guerra et al. state that “Hepcidin transcription in hepatocytes is driven by a BMP–SMAD pathway” involving BMP ligands and SMAD1/5/8 activation. (guerra2023novelpotentialtherapeutics pages 1-3)

Silvestri et al. describe TMPRSS6 as a key inhibitor: “the main hepcidin inhibitor is type II transmembrane serine protease 6 (TMPRSS6 or matriptase-2).” (silvestri2023managingthedual pages 9-11)

Wake et al. integrate this with β-thalassemia, noting IE is associated with “down-regulation of hepcidin and up-regulation of ferroportin,” increasing iron absorption. (wake2024ahumanantimatriptase2 pages 9-10)

(C) EPO–EPOR–JAK2–ERFE axis: erythroid-to-liver signaling

Guerra et al. connect erythropoietic drive to iron regulation: “EPO acts via EPOR → JAK2 phosphorylation to activate downstream genes including erythroferrone (ERFE),” which links erythroid stress to hepcidin suppression. (guerra2023novelpotentialtherapeutics pages 1-3)

(D) Cellular iron distribution and iron overload compartments

Iron loading results in transferrin saturation and NTBI deposition. Narahari et al. state: “Inefficient iron utilization… results in transferrin saturation and eventually the accumulation of NTBI in secondary sites such as the liver, cardiac tissue, and endocrine glands.” (narahari2024exploringtheimpact pages 1-2)

2.3 Oxidative stress, mitochondrial dysfunction, ferroptosis

(A) ROS and mitochondrial injury

Narahari et al. highlight mitochondrial mechanisms: “iron overload can impair the electron transport chain, reduce adenosine tri phosphate synthesis, and increase the generation of reactive oxygen species.” (narahari2024exploringtheimpact pages 1-2)

(B) Ferroptosis and its coupling to ineffective erythropoiesis

Lin et al. review ferroptosis as “an iron-dependent lipid peroxidation” and position it as mechanistically intertwined with IE via shared dependencies on iron and ROS homeostasis. (lin2024theinteractionsbetween pages 1-2)

They also cite an estimate of intramedullary precursor loss: “around 65% of nucleated erythrocytes perish before maturation.” (lin2024theinteractionsbetween pages 1-2)

3) Key molecular players (genes/proteins, chemicals, cells, anatomy)

3.1 Genes/proteins (HGNC-style list with roles)

Causal / primary: - HBB (β-globin): mutations cause reduced/absent β-globin; initiates globin imbalance. (liang2023elevatedcdkn1a(p21) pages 1-2, daniels2023humancellularmodel pages 1-2) - HBA1/HBA2 (α-globin): excess free α-globin is the proximate toxic species; aggregates drive ROS and IE. (traegersynodinos2024impactofαglobin pages 1-2)

Erythroid injury / apoptosis: - FOXO3, CDKN1A (p21), TP53: implicated in regulation of erythroid apoptosis in β-thalassemia models. (liang2023elevatedcdkn1a(p21) pages 1-2)

Iron regulation network: - HAMP (hepcidin): master systemic regulator. (guerra2023novelpotentialtherapeutics pages 1-3) - SLC40A1 (ferroportin/FPN1): iron exporter inhibited by hepcidin. (guerra2023novelpotentialtherapeutics pages 1-3, silvestri2023managingthedual pages 9-11) - TMPRSS6 (matriptase-2): “main hepcidin inhibitor”; therapeutic target to raise hepcidin. (silvestri2023managingthedual pages 9-11, wake2024ahumanantimatriptase2 pages 1-2) - ERFE (erythroferrone): erythroid-derived hepcidin suppressor induced downstream of EPO signaling. (guerra2023novelpotentialtherapeutics pages 1-3, settakorn2024arandomizedplacebo−controlled pages 1-2) - BMP6/BMP2, SMAD1/5/8 (hepcidin induction), and SMAD2/3 (TGF-β superfamily signaling targeted by luspatercept-like ligands). (guerra2023novelpotentialtherapeutics pages 1-3, wake2024ahumanantimatriptase2 pages 1-2) - HFE, TFR1, TFR2, HJV: hepatic iron-sensing/BMP coregulation components. (guerra2023novelpotentialtherapeutics pages 1-3, silvestri2023managingthedual pages 9-11)

Proteostasis/autophagy modifiers: - AHSP (α-hemoglobin stabilizing protein): candidate buffer against α-globin toxicity. (traegersynodinos2024impactofαglobin pages 1-2, gambari2024therapeuticrelevanceof pages 1-3) - ULK1, PI3K/AKT/mTOR axis: autophagy regulation proposed to reduce α-globin excess/aggregates. (gambari2024therapeuticrelevanceof pages 1-3)

3.2 Chemical entities (CHEBI-style)

  • Iron (Fe), heme, non-transferrin-bound iron (NTBI). (narahari2024exploringtheimpact pages 1-2)
  • Reactive oxygen species (ROS) (chemical class). (daniels2023humancellularmodel pages 1-2)
  • Epigallocatechin-3-gallate (EGCG) (green tea catechin; iron-chelating/antioxidant properties in TDT trial). (settakorn2024arandomizedplacebo−controlled pages 1-2)

3.3 Cell types (CL-style)

  • Erythroid progenitors/erythroblasts (bone marrow erythroblastic islands): site of α-globin precipitation, ROS, apoptosis, and maturation arrest. (daniels2023humancellularmodel pages 1-2, liang2023elevatedcdkn1a(p21) pages 1-2)
  • Reticuloendothelial macrophages (especially splenic): RBC clearance and iron recycling to transferrin via ferroportin. (silvestri2023managingthedual pages 9-11)
  • Hepatocytes (hepcidin production) and liver sinusoidal endothelial cells (BMP2/BMP6 expression). (silvestri2023managingthedual pages 9-11)
  • Duodenal enterocytes: iron absorption regulated by hepcidin–ferroportin axis. (silvestri2023managingthedual pages 9-11)

3.4 Anatomical locations (UBERON-style)

  • Bone marrow (primary erythropoiesis, apoptosis/IE). (daniels2023humancellularmodel pages 1-2, liang2023elevatedcdkn1a(p21) pages 6-7)
  • Spleen (extramedullary erythropoiesis; splenomegaly; iron recycling). (liang2023elevatedcdkn1a(p21) pages 1-2, silvestri2023managingthedual pages 9-11)
  • Liver (hepcidin synthesis; major iron deposition site; NTBI toxicity). (narahari2024exploringtheimpact pages 1-2, silvestri2023managingthedual pages 9-11)
  • Heart and endocrine glands (secondary iron deposition and dysfunction). (narahari2024exploringtheimpact pages 1-2)

4) Biological processes (GO-style) disrupted

Supported by the above evidence, disrupted processes include: - Hemoglobin biosynthetic process / hemoglobin complex assembly (globin imbalance as initiating lesion). (liang2023elevatedcdkn1a(p21) pages 1-2, daniels2023humancellularmodel pages 1-2) - Erythrocyte differentiation with a polychromatic-stage maturation block and increased apoptosis. (daniels2023humancellularmodel pages 1-2) - Erythroblast apoptotic process / response to oxidative stress (α-globin auto-oxidation → ROS → apoptosis). (daniels2023humancellularmodel pages 1-2, liang2023elevatedcdkn1a(p21) pages 1-2) - Iron ion homeostasis / iron ion transport governed by hepcidin–ferroportin. (guerra2023novelpotentialtherapeutics pages 1-3, silvestri2023managingthedual pages 9-11) - Regulation of hepcidin production via BMP–SMAD and negative regulation by TMPRSS6. (guerra2023novelpotentialtherapeutics pages 1-3, silvestri2023managingthedual pages 9-11) - Autophagy as an adaptive process to clear α-globin aggregates; regulated by ULK1 and PI3K/AKT/mTOR. (gambari2024therapeuticrelevanceof pages 1-3) - Lipid peroxidation / ferroptosis as iron-dependent oxidative death pathway interacting with IE. (lin2024theinteractionsbetween pages 1-2)

5) Cellular components (GO-CC-style) implicated

  • Erythrocyte cytosol and hemoglobin complex (site of globin imbalance). (daniels2023humancellularmodel pages 1-2)
  • Erythrocyte membrane (ROS-mediated membrane damage; membrane-associated α-globin aggregates). (traegersynodinos2024impactofαglobin pages 1-2)
  • Mitochondrion (iron overload → ETC impairment and ROS generation). (narahari2024exploringtheimpact pages 1-2)
  • Autophagosome / lysosome-related clearance machinery (autophagy-based α-globin reduction). (gambari2024therapeuticrelevanceof pages 1-3)
  • Hepatocyte plasma membrane signaling complexes (BMP receptors/SMAD signaling; TMPRSS6 regulation). (guerra2023novelpotentialtherapeutics pages 1-3, silvestri2023managingthedual pages 9-11)

6) Disease progression: sequence of events (trigger → clinical manifestations)

6.1 Initiation (genotype to molecular lesion)

HBB mutations reduce β-globin synthesis and cause α/β imbalance. (liang2023elevatedcdkn1a(p21) pages 1-2, daniels2023humancellularmodel pages 1-2)

6.2 Early cellular pathophysiology (erythroid compartment)

Excess α-globin aggregates, ROS, and apoptosis drive IE; Daniels et al. describe a polychromatic-stage block. (daniels2023humancellularmodel pages 1-2)

6.3 Systemic compensation and hematopoietic remodeling

Anemia increases EPO, expanding erythroid progenitors, promoting extramedullary erythropoiesis and splenomegaly. (liang2023elevatedcdkn1a(p21) pages 1-2)

6.4 Iron overload development

Iron overload arises from both: - Erythropoiesis-driven hepcidin suppression (↑ ferroportin, ↑ intestinal absorption). (wake2024ahumanantimatriptase2 pages 9-10, guerra2023novelpotentialtherapeutics pages 1-3) - Transfusional iron loading in TDT. (narahari2024exploringtheimpact pages 1-2, settakorn2024arandomizedplacebo−controlled pages 1-2)

6.5 End-organ toxicity

With transferrin saturation, NTBI deposits in liver/heart/endocrine organs. (narahari2024exploringtheimpact pages 1-2)

7) Phenotypic manifestations (HP-style) linked to mechanisms

  • Hemolytic anemia / chronic anemia (HP: anemia) from IE and hemolysis. (liang2023elevatedcdkn1a(p21) pages 1-2, daniels2023humancellularmodel pages 1-2)
  • Splenomegaly due to extramedullary erythropoiesis and RBC clearance. (liang2023elevatedcdkn1a(p21) pages 1-2)
  • Iron overload (HP: iron overload) with liver/cardiac/endocrine deposition and oxidative tissue damage. (narahari2024exploringtheimpact pages 1-2)

8) Recent developments and latest research (prioritizing 2023–2024)

8.1 Human cellular models enabling mechanistic profiling and target discovery (2023)

Daniels et al. (Nature Communications; accepted 26 Sep 2023; published Oct 2023 per citation metadata) developed gene-edited BEL-A erythroid lines that “accurately recapitulate the phenotype of patient erythroid cells” and enable “extensive analysis of the altered molecular mechanisms” via proteomics and a “high throughput compatible fluorometric-based assay” to quantify IE severity. (daniels2023humancellularmodel pages 1-2)

Their mechanistic framing reiterates globin imbalance→ROS as primary cause (quote in §1.1). (daniels2023humancellularmodel pages 1-2)

8.2 Ferroptosis as an emerging mechanistic layer (2024)

Lin et al. (Frontiers in Physiology; Feb 2024) synthesize evidence that ferroptosis (iron-dependent lipid peroxidation) may interact with IE through shared iron/ROS dysregulation, proposing ferroptosis as a therapeutic concept for β-thalassemia. (lin2024theinteractionsbetween pages 1-2)

8.3 TMPRSS6 (matriptase-2) as a therapeutic lever to correct iron overload and improve erythropoiesis (2024)

Wake et al. (Blood Advances; Apr 2024; DOI 10.1182/bloodadvances.2023012010) report that a human anti-matriptase-2 antibody can raise hepcidin and “limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice,” supporting TMPRSS6 inhibition as a strategy to restore the hepcidin–ferroportin brake on iron loading. (wake2024ahumanantimatriptase2 pages 9-10)

Wake et al. also cite mechanistic linkage between matriptase-2, hepatic BMP–SMAD signaling, and hepcidin regulation: “Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.” (wake2024ahumanantimatriptase2 pages 9-10)

8.4 Autophagy induction to reduce α-globin toxicity (2024)

Gambari & Finotti (Cells; May 2024) position autophagy as an approach to lower excess free α-globin chains and aggregates; autophagy is “regulated by the Unc-51-like kinase 1 (Ulk1) gene” and interacts with the “PI3K/Akt/TOR pathway” and AHSP/microRNA regulation. (gambari2024therapeuticrelevanceof pages 1-3)

Traeger‑Synodinos et al. (IJMS; Mar 2024) similarly identify AHSP and autophagy as modifiers to counteract α-globin excess. (traegersynodinos2024impactofαglobin pages 1-2)

8.5 Clinical modulation of erythropoiesis regulators and oxidative stress with EGCG (2024 trial)

Settakorn et al. (Frontiers in Molecular Biosciences; published 24 Jan 2024; DOI 10.3389/fmolb.2023.1248742) conducted a “randomized placebo−controlled clinical trial” in “Twenty−seven TDT patients… for 60 days,” reporting that GTE tablets “lowered plasma levels of erythroferrone (p < 0.05)” alongside signals consistent with improved hemolysis/erythropoiesis modulation. (settakorn2024arandomizedplacebo−controlled pages 1-2)

9) Current applications and real-world implementations (mechanism-linked)

9.1 Standard-of-care implementations

  • Regular blood transfusions in TDT to maintain hemoglobin and suppress extreme erythropoietic stress, but with iron loading risk. (settakorn2024arandomizedplacebo−controlled pages 1-2, daniels2023humancellularmodel pages 1-2)
  • Iron chelation therapy to mitigate organ iron deposition/toxicity, often lifelong in transfused patients. (settakorn2024arandomizedplacebo−controlled pages 1-2)

9.2 Mechanism-based newer/adjunct approaches

  • TGF-β superfamily ligand trapping to improve late-stage erythroid maturation (luspatercept class): Wake et al. describe RAP-536L (murine analog) that “sequesters ligands of the TGF-β superfamily… particularly GDF8 and GDF11” inhibiting SMAD2/3 to promote erythroid differentiation; combination with TMPRSS6 antibody improved multiple disease axes in mice. (wake2024ahumanantimatriptase2 pages 1-2)
  • Restoring hepcidin signaling / limiting ferroportin-mediated iron entry via TMPRSS6 targeting (preclinical in 2024). (wake2024ahumanantimatriptase2 pages 9-10, silvestri2023managingthedual pages 9-11)
  • Antioxidant/iron-chelation nutraceutical adjuncts (EGCG/GTE): small randomized trial indicates ERFE modulation (p<0.05). (settakorn2024arandomizedplacebo−controlled pages 1-2)

10) Expert opinions / authoritative synthesis (from reviews)

10.1 Hepcidin regulation is multi-signal, multi-cell-type, and still mechanistically incomplete

Silvestri et al. emphasize that hepcidin regulation integrates iron and erythropoiesis and involves intraorgan crosstalk (hepatocytes ↔ liver sinusoidal endothelial cells). They also highlight unresolved details (e.g., how iron regulates BMP6 and how HFE/TFR2 signal through BMP–SMAD). (silvestri2023managingthedual pages 9-11)

10.2 Therapeutics that improve erythropoiesis can secondarily improve iron metabolism (and vice versa)

Guerra et al. synthesize that “improvements in red blood cell production also ameliorate iron metabolism and vice versa” (review theme), framing a coupled axis as central to next-generation therapeutics in β-thalassemia. (guerra2023novelpotentialtherapeutics pages 1-3)

11) Recent statistics and quantitative data (from included sources)

11.1 Epidemiology / burden

  • Global burden estimates in a 2023 source: “80–90 million carriers (~1.5% global)” and “~60,000 symptomatic births/year” are reported in Zahed 2023. (zahed2023effectiveutilizationof pages 58-61)
  • Basu 2023 reports “~56,000 infants born with severe thalassemia annually worldwide” and India-specific estimates (e.g., ~10,000–12,000 thalassemia major births/year; ~42 million carriers; prevalence ~3–4%). (basu2023understandingtheintricacies pages 1-2)

11.2 Quantification of ineffective erythropoiesis

  • Lin 2024 cites that “around 65% of nucleated erythrocytes perish before maturation,” illustrating the magnitude of intramedullary loss in IE. (lin2024theinteractionsbetween pages 1-2)

11.3 Clinical trial numeric elements (2024)

  • Settakorn 2024: n=27 TDT randomized to placebo vs GTE tablets (50 or 100 mg EGCG equivalent) for 60 days; reported lowering of plasma ERFE with p < 0.05. (settakorn2024arandomizedplacebo−controlled pages 1-2)

12) Knowledge-base style annotations (entities and ontology mappings)

12.1 Pathophysiology description (knowledge-base narrative)

β-thalassemia is caused by HBB variants that reduce β-globin synthesis, producing α/β-globin imbalance. Excess free α-globin forms insoluble aggregates and undergoes auto-oxidation, driving ROS generation and oxidative membrane/cellular injury in erythroid precursors, leading to apoptosis, a polychromatic-stage maturation block, and ineffective erythropoiesis; peripheral hemolysis contributes further to anemia. Anemia elevates EPO signaling, expanding erythroid progenitors and promoting extramedullary erythropoiesis and splenomegaly. Ineffective erythropoiesis and erythroid signaling (ERFE) suppress hepatic hepcidin, increasing ferroportin-mediated iron export and intestinal absorption; transfusion therapy adds exogenous iron. Progressive transferrin saturation leads to NTBI and iron deposition in liver, heart, and endocrine tissues, causing ROS/mitochondrial dysfunction and organ toxicity. (daniels2023humancellularmodel pages 1-2, liang2023elevatedcdkn1a(p21) pages 1-2, guerra2023novelpotentialtherapeutics pages 1-3, narahari2024exploringtheimpact pages 1-2)

12.2 Gene/protein annotations (HGNC; with mechanistic evidence)

  • HBB: Reduced/absent β-globin → α-globin excess → aggregates/ROS/IE. (daniels2023humancellularmodel pages 1-2, liang2023elevatedcdkn1a(p21) pages 1-2)
  • HBA1/HBA2: α-globin excess is deleterious; forms precipitates and ROS leading to membrane damage and IE. (traegersynodinos2024impactofαglobin pages 1-2)
  • FOXO3, CDKN1A (P21): regulators of erythroid apoptosis in Hbbth3/+ model; loss reduces apoptosis but does not necessarily resolve IE. (liang2023elevatedcdkn1a(p21) pages 1-2, liang2023elevatedcdkn1a(p21) pages 6-7)
  • HAMP (hepcidin): liver hormone controlling systemic iron via ferroportin. (guerra2023novelpotentialtherapeutics pages 1-3)
  • SLC40A1 (ferroportin/FPN1): iron exporter on enterocytes/macrophages/hepatocytes inhibited by hepcidin. (guerra2023novelpotentialtherapeutics pages 1-3, silvestri2023managingthedual pages 9-11)
  • TMPRSS6: “main hepcidin inhibitor”; targeting can increase hepcidin and limit iron overload in β-thalassemia models. (silvestri2023managingthedual pages 9-11, wake2024ahumanantimatriptase2 pages 9-10)
  • ERFE (erythroferrone): downstream of EPO signaling; suppresses hepcidin; modulated in a 2024 TDT trial. (guerra2023novelpotentialtherapeutics pages 1-3, settakorn2024arandomizedplacebo−controlled pages 1-2)
  • ULK1 / PI3K-AKT-mTOR axis / AHSP: autophagy-based and chaperone-based modifiers of α-globin toxicity (reviewed). (gambari2024therapeuticrelevanceof pages 1-3, traegersynodinos2024impactofαglobin pages 1-2)

12.3 GO biological process candidates (non-exhaustive)

  • Hemoglobin biosynthetic process; erythrocyte differentiation; erythroblast apoptotic process; response to oxidative stress; iron ion homeostasis; regulation of hepcidin production; iron ion transport; autophagy; BMP signaling pathway; TGF-β receptor signaling; lipid peroxidation/ferroptosis. (daniels2023humancellularmodel pages 1-2, guerra2023novelpotentialtherapeutics pages 1-3, lin2024theinteractionsbetween pages 1-2)

12.4 GO cellular component candidates

  • Hemoglobin complex; erythrocyte cytosol; erythrocyte membrane; mitochondrion; autophagosome; hepatocyte plasma membrane signaling complexes. (narahari2024exploringtheimpact pages 1-2, gambari2024therapeuticrelevanceof pages 1-3)

12.5 Phenotype associations (HP-style)

  • Anemia; hemolytic anemia; ineffective erythropoiesis; splenomegaly; iron overload; liver iron deposition; cardiomyopathy/heart involvement; endocrine dysfunction. (liang2023elevatedcdkn1a(p21) pages 1-2, narahari2024exploringtheimpact pages 1-2)

12.6 Cell type involvement (CL-style)

  • Erythroid progenitor/erythroblast; mature erythrocyte; reticuloendothelial macrophage; hepatocyte; liver sinusoidal endothelial cell; duodenal enterocyte. (silvestri2023managingthedual pages 9-11, daniels2023humancellularmodel pages 1-2)

12.7 Anatomical locations (UBERON-style)

  • Bone marrow; spleen; liver; duodenum/small intestine; heart; endocrine glands. (narahari2024exploringtheimpact pages 1-2, silvestri2023managingthedual pages 9-11)

12.8 Chemical entities (CHEBI-style)

  • Iron; heme; NTBI; ROS; EGCG; iron chelators (DFO/DFP/DFX). (settakorn2024arandomizedplacebo−controlled pages 1-2)

13) Evidence items (PMID/DOI/URL/date)

Note: The provided full texts include DOIs and dates; PMIDs were not present in the retrieved excerpts for several items.

1) Daniels DE et al. Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype. Nature Communications. Accepted 26 Sep 2023 (as shown in article header). DOI: 10.1038/s41467-023-41961-9. URL: https://doi.org/10.1038/s41467-023-41961-9 (daniels2023humancellularmodel pages 1-2, daniels2023humancellularmodel pages 9-10)

2) Liang R et al. Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis… Blood Advances. Prepublished online 6 Sep 2023; volume date 28 Nov 2023 (as shown). DOI: 10.1182/bloodadvances.2022007655. URL: https://doi.org/10.1182/bloodadvances.2022007655 (liang2023elevatedcdkn1a(p21) pages 1-2, liang2023elevatedcdkn1a(p21) pages 6-7)

3) Wake M et al. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice. Blood Advances. Apr 2024. DOI: 10.1182/bloodadvances.2023012010. URL: https://doi.org/10.1182/bloodadvances.2023012010 (wake2024ahumanantimatriptase2 pages 9-10, wake2024ahumanantimatriptase2 pages 1-2)

4) Lin S et al. The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia. Frontiers in Physiology. Feb 2024. DOI: 10.3389/fphys.2024.1346173. URL: https://doi.org/10.3389/fphys.2024.1346173 (lin2024theinteractionsbetween pages 1-2)

5) Settakorn K et al. A randomized placebo-controlled clinical trial of oral green tea EGCG on erythropoiesis and oxidative stress in TDT β-thalassemia patients. Frontiers in Molecular Biosciences. Published 24 Jan 2024. DOI: 10.3389/fmolb.2023.1248742. URL: https://doi.org/10.3389/fmolb.2023.1248742 (settakorn2024arandomizedplacebo−controlled pages 1-2, settakorn2024arandomizedplacebo−controlled pages 6-7)

6) Traeger‑Synodinos J et al. Impact of α-globin gene expression and α-globin modifiers on β-thalassemia phenotype. International Journal of Molecular Sciences. Published 17 Mar 2024. DOI: 10.3390/ijms25063400. URL: https://doi.org/10.3390/ijms25063400 (traegersynodinos2024impactofαglobin pages 1-2)

7) Gambari R, Finotti A. Therapeutic relevance of inducing autophagy in β-thalassemia. Cells. May 2024. DOI: 10.3390/cells13110918. URL: https://doi.org/10.3390/cells13110918 (gambari2024therapeuticrelevanceof pages 1-3)

8) Guerra A et al. Novel potential therapeutics to modify iron metabolism and red cell synthesis… Haematologica. Jun 2023. DOI: 10.3324/haematol.2023.283057. URL: https://doi.org/10.3324/haematol.2023.283057 (guerra2023novelpotentialtherapeutics pages 1-3)

9) Silvestri L et al. Managing the dual nature of iron to preserve health. International Journal of Molecular Sciences. Feb 2023. DOI: 10.3390/ijms24043995. URL: https://doi.org/10.3390/ijms24043995 (silvestri2023managingthedual pages 9-11)

10) Narahari JM et al. Exploring the impact of iron overload on mitochondrial DNA in β-thalassemia. Gene Expression. Apr 2024. DOI: 10.14218/ge.2023.00128. URL: https://doi.org/10.14218/ge.2023.00128 (narahari2024exploringtheimpact pages 1-2)

11) Basu S et al. Understanding the intricacies of iron overload associated with β-thalassemia. Thalassemia Reports. Jul 2023. DOI: 10.3390/thalassrep13030017. URL: https://doi.org/10.3390/thalassrep13030017 (basu2023understandingtheintricacies pages 1-2)

Limitations of this report

  • Several mechanistic claims in the included reviews cite foundational primary literature (often pre-2023). Where those underlying primary papers would be needed for strict “PMID for all mechanistic claims,” the current tool session did not retrieve those specific primary full texts/PMIDs; therefore, DOIs and direct quotes from the available 2023–2024/2023 sources were used wherever possible. (sadiq2024thalassemiapathophysiologydiagnosis pages 17-18)

References

  1. (liang2023elevatedcdkn1a(p21) pages 1-2): Raymond Liang, Miao Lin, Vijay Menon, Jiajing Qiu, Anagha Menon, Laura Breda, Tasleem Arif, Stefano Rivella, and Saghi Ghaffari. Elevated cdkn1a (p21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis. Blood Advances, 7:6873-6885, Nov 2023. URL: https://doi.org/10.1182/bloodadvances.2022007655, doi:10.1182/bloodadvances.2022007655. This article has 5 citations and is from a peer-reviewed journal.

  2. (daniels2023humancellularmodel pages 1-2): Deborah E. Daniels, Ivan Ferrer-Vicens, Joseph Hawksworth, Tatyana N. Andrienko, Elizabeth M. Finnie, Natalie S. Bretherton, Daniel C. J. Ferguson, A. Sofia. F. Oliveira, Jenn-Yeu A. Szeto, Marieangela C. Wilson, John N. Brewin, and Jan Frayne. Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype. Nature Communications, Oct 2023. URL: https://doi.org/10.1038/s41467-023-41961-9, doi:10.1038/s41467-023-41961-9. This article has 8 citations and is from a highest quality peer-reviewed journal.

  3. (basu2023understandingtheintricacies pages 1-2): Subhangi Basu, Motiur Rahaman, Tuphan Kanti Dolai, Praphulla Chandra Shukla, and Nishant Chakravorty. Understanding the intricacies of iron overload associated with β-thalassemia: a comprehensive review. Thalassemia Reports, Jul 2023. URL: https://doi.org/10.3390/thalassrep13030017, doi:10.3390/thalassrep13030017. This article has 23 citations.

  4. (traegersynodinos2024impactofαglobin pages 1-2): Joanne Traeger-Synodinos, Christina Vrettou, Christalena Sofocleous, Matteo Zurlo, Alessia Finotti, and Roberto Gambari. Impact of α-globin gene expression and α-globin modifiers on the phenotype of β-thalassemia and other hemoglobinopathies: implications for patient management. International Journal of Molecular Sciences, 25(6):3400, Mar 2024. URL: https://doi.org/10.3390/ijms25063400, doi:10.3390/ijms25063400. This article has 14 citations.

  5. (wake2024ahumanantimatriptase2 pages 9-10): Matthew Wake, Anaïs Palin, Audrey Belot, Mathieu Berger, Megane Lorgouilloux, Margot Bichon, Jonathan Papworth, Luke Bayliss, Benjamin Grimshaw, Natalie Rynkiewicz, Jemima Paterson, Alicia Poindron, Erin Spearing, Emily Carter, Robyne Hudson, Millie Campbell, Verena Petzer, Céline Besson-Fournier, Chloé Latour, Amélie Largounez, Ophélie Gourbeyre, Alexis Fay, Hélène Coppin, Marie-Paule Roth, Igor Theurl, Volker Germaschewski, and Delphine Meynard. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice. Blood Advances, 8:1898-1907, Apr 2024. URL: https://doi.org/10.1182/bloodadvances.2023012010, doi:10.1182/bloodadvances.2023012010. This article has 7 citations and is from a peer-reviewed journal.

  6. (guerra2023novelpotentialtherapeutics pages 1-3): Amaliris Guerra, Hamideh Parhiz, and Stefano Rivella. Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis. Haematologica, 108:2582-2593, Jun 2023. URL: https://doi.org/10.3324/haematol.2023.283057, doi:10.3324/haematol.2023.283057. This article has 20 citations.

  7. (narahari2024exploringtheimpact pages 1-2): Jyothi M. Narahari, Prajwal Guruswamy, Navyashree M. Jagadeesha, Kusuma K. Shivashakar, Divya P. Kumar, Prashanth S. Narayana, Prashant M. Vishwanath, and Akila Prashant. Exploring the impact of iron overload on mitochondrial dna in β-thalassemia: a comprehensive review. Gene Expression, 000:000-000, Apr 2024. URL: https://doi.org/10.14218/ge.2023.00128, doi:10.14218/ge.2023.00128. This article has 9 citations and is from a peer-reviewed journal.

  8. (liang2023elevatedcdkn1a(p21) pages 6-7): Raymond Liang, Miao Lin, Vijay Menon, Jiajing Qiu, Anagha Menon, Laura Breda, Tasleem Arif, Stefano Rivella, and Saghi Ghaffari. Elevated cdkn1a (p21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis. Blood Advances, 7:6873-6885, Nov 2023. URL: https://doi.org/10.1182/bloodadvances.2022007655, doi:10.1182/bloodadvances.2022007655. This article has 5 citations and is from a peer-reviewed journal.

  9. (silvestri2023managingthedual pages 9-11): Laura Silvestri, Mariateresa Pettinato, Valeria Furiosi, Letizia Bavuso Volpe, Antonella Nai, and Alessia Pagani. Managing the dual nature of iron to preserve health. International Journal of Molecular Sciences, 24:3995, Feb 2023. URL: https://doi.org/10.3390/ijms24043995, doi:10.3390/ijms24043995. This article has 43 citations.

  10. (lin2024theinteractionsbetween pages 1-2): Siyang Lin, Yanping Zheng, Meihuan Chen, Liangpu Xu, and Hailong Huang. The interactions between ineffective erythropoiesis and ferroptosis in β-thalassemia. Frontiers in Physiology, Feb 2024. URL: https://doi.org/10.3389/fphys.2024.1346173, doi:10.3389/fphys.2024.1346173. This article has 17 citations.

  11. (wake2024ahumanantimatriptase2 pages 1-2): Matthew Wake, Anaïs Palin, Audrey Belot, Mathieu Berger, Megane Lorgouilloux, Margot Bichon, Jonathan Papworth, Luke Bayliss, Benjamin Grimshaw, Natalie Rynkiewicz, Jemima Paterson, Alicia Poindron, Erin Spearing, Emily Carter, Robyne Hudson, Millie Campbell, Verena Petzer, Céline Besson-Fournier, Chloé Latour, Amélie Largounez, Ophélie Gourbeyre, Alexis Fay, Hélène Coppin, Marie-Paule Roth, Igor Theurl, Volker Germaschewski, and Delphine Meynard. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice. Blood Advances, 8:1898-1907, Apr 2024. URL: https://doi.org/10.1182/bloodadvances.2023012010, doi:10.1182/bloodadvances.2023012010. This article has 7 citations and is from a peer-reviewed journal.

  12. (settakorn2024arandomizedplacebo−controlled pages 1-2): Kornvipa Settakorn, Sasinee Hantrakool, Touchwin Petiwathayakorn, Nuntouchaporn Hutachok, Adisak Tantiworawit, Pimlak Charoenkwan, Nopphadol Chalortham, Anchan Chompupoung, Narisara Paradee, Pimpisid Koonyosying, and Somdet Srichairatanakool. A randomized placebo−controlled clinical trial of oral green tea epigallocatechin 3−gallate on erythropoiesis and oxidative stress in transfusion−dependent β−thalassemia patients. Frontiers in Molecular Biosciences, Jan 2024. URL: https://doi.org/10.3389/fmolb.2023.1248742, doi:10.3389/fmolb.2023.1248742. This article has 7 citations.

  13. (gambari2024therapeuticrelevanceof pages 1-3): Roberto Gambari and Alessia Finotti. Therapeutic relevance of inducing autophagy in β-thalassemia. Cells, 13:918, May 2024. URL: https://doi.org/10.3390/cells13110918, doi:10.3390/cells13110918. This article has 1 citations.

  14. (zahed2023effectiveutilizationof pages 58-61): R Zahed. Effective utilization of molecular genetic screening of patients with sickle cell disease and beta thalassemia major in saudi arabia. Unknown journal, 2023.

  15. (daniels2023humancellularmodel pages 9-10): Deborah E. Daniels, Ivan Ferrer-Vicens, Joseph Hawksworth, Tatyana N. Andrienko, Elizabeth M. Finnie, Natalie S. Bretherton, Daniel C. J. Ferguson, A. Sofia. F. Oliveira, Jenn-Yeu A. Szeto, Marieangela C. Wilson, John N. Brewin, and Jan Frayne. Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype. Nature Communications, Oct 2023. URL: https://doi.org/10.1038/s41467-023-41961-9, doi:10.1038/s41467-023-41961-9. This article has 8 citations and is from a highest quality peer-reviewed journal.

  16. (settakorn2024arandomizedplacebo−controlled pages 6-7): Kornvipa Settakorn, Sasinee Hantrakool, Touchwin Petiwathayakorn, Nuntouchaporn Hutachok, Adisak Tantiworawit, Pimlak Charoenkwan, Nopphadol Chalortham, Anchan Chompupoung, Narisara Paradee, Pimpisid Koonyosying, and Somdet Srichairatanakool. A randomized placebo−controlled clinical trial of oral green tea epigallocatechin 3−gallate on erythropoiesis and oxidative stress in transfusion−dependent β−thalassemia patients. Frontiers in Molecular Biosciences, Jan 2024. URL: https://doi.org/10.3389/fmolb.2023.1248742, doi:10.3389/fmolb.2023.1248742. This article has 7 citations.

  17. (sadiq2024thalassemiapathophysiologydiagnosis pages 17-18): Idris Zubairu Sadiq, Fatima Sadiq Abubakar, Hauwa Salisu Usman, Aliyu Dantani Abdullahi, Bashiru Ibrahim, Babangida Sanusi Kastayal, Maryam Ibrahim, and Hassan Aliyu Hassan. Thalassemia: pathophysiology, diagnosis, and advances in treatment. Thalassemia Reports, 14:81-102, Oct 2024. URL: https://doi.org/10.3390/thalassrep14040010, doi:10.3390/thalassrep14040010. This article has 48 citations.